{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:11Z","timestamp":1768867211786,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103430"],"award-info":[{"award-number":["P20GM103430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","award":["2017 Pinnacle Research Award"],"award-info":[{"award-number":["2017 Pinnacle Research Award"]}],"id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014082","name":"Rhode Island Foundation","doi-asserted-by":"crossref","award":["134279"],"award-info":[{"award-number":["134279"]}],"id":[{"id":"10.13039\/100014082","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10620-020-06330-2","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:03:21Z","timestamp":1590138201000},"page":"1080-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis"],"prefix":"10.1007","volume":"66","author":[{"given":"Katsuya","family":"Nagaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Y.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joud","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Wands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-7898","authenticated-orcid":false,"given":"Chiung-Kuei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"6330_CR1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168\u20132179.","journal-title":"Lancet"},{"key":"6330_CR2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72\u201379.","journal-title":"Oncologist"},{"key":"6330_CR3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427\u20131434.","journal-title":"Hepatology"},{"key":"6330_CR4","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474\u20131478.","journal-title":"Nat Genet"},{"key":"6330_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","volume":"9","author":"CD Anderson","year":"2004","unstructured":"Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9:43\u201357.","journal-title":"Oncologist"},{"key":"6330_CR6","first-page":"155","volume":"4","author":"KR Eckmann","year":"2011","unstructured":"Eckmann KR, Patel DK, Landgraf A, et al. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res. 2011;4:155\u2013160.","journal-title":"Gastrointest Cancer Res"},{"key":"6330_CR7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181\u2013188.","journal-title":"Lancet Oncol"},{"key":"6330_CR8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI118918","volume":"98","author":"L Lavaissiere","year":"1996","unstructured":"Lavaissiere L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest. 1996;98:1313\u20131323.","journal-title":"J Clin Invest"},{"key":"6330_CR9","doi-asserted-by":"crossref","first-page":"e0150336","DOI":"10.1371\/journal.pone.0150336","volume":"11","author":"CK Huang","year":"2016","unstructured":"Huang CK, Iwagami Y, Aihara A, et al. Anti-tumor effects of second generation beta-hydroxylase inhibitors on cholangiocarcinoma development and progression. PLoS ONE. 2016;11:e0150336.","journal-title":"PLoS ONE"},{"key":"6330_CR10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2016.05.038","volume":"380","author":"CK Huang","year":"2016","unstructured":"Huang CK, Aihara A, Iwagami Y, et al. Expression of transforming growth factor beta1 promotes cholangiocarcinoma development and progression. Cancer Lett. 2016;380:153\u2013162.","journal-title":"Cancer Lett"},{"key":"6330_CR11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/hep.21272","volume":"44","author":"MC Cantarini","year":"2006","unstructured":"Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44:446\u2013457.","journal-title":"Hepatology"},{"key":"6330_CR12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.18632\/oncotarget.2840","volume":"6","author":"X Dong","year":"2015","unstructured":"Dong X, Lin Q, Aihara A, et al. Aspartate beta-Hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget. 2015;6:1231\u20131248.","journal-title":"Oncotarget"},{"key":"6330_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cdp.2004.06.001","volume":"28","author":"T Maeda","year":"2004","unstructured":"Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev. 2004;28:313\u2013318.","journal-title":"Cancer Detect Prev"},{"key":"6330_CR14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0168-8278(03)00052-7","volume":"38","author":"T Maeda","year":"2003","unstructured":"Maeda T, Sepe P, Lahousse S, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol. 2003;38:615\u2013622.","journal-title":"J Hepatol"},{"key":"6330_CR15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.27275","volume":"60","author":"A Aihara","year":"2014","unstructured":"Aihara A, Huang CK, Olsen MJ, et al. A cell-surface beta-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:1302\u20131313.","journal-title":"Hepatology"},{"key":"6330_CR16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.22088","volume":"47","author":"AE Sirica","year":"2008","unstructured":"Sirica AE, Zhang Z, Lai GH, et al. A novel \u201cpatient-like\u201d model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008;47:1178\u20131190.","journal-title":"Hepatology"},{"key":"6330_CR17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.24629","volume":"55","author":"T Noda","year":"2012","unstructured":"Noda T, Shimoda M, Ortiz V, Sirica AE, Wands JR. Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology. 2012;55:86\u201397.","journal-title":"Hepatology"},{"key":"6330_CR18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00006676-200207000-00010","volume":"25","author":"KS Palumbo","year":"2002","unstructured":"Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas. 2002;25:39\u201344.","journal-title":"Pancreas"},{"key":"6330_CR19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.28411","volume":"63","author":"Y Iwagami","year":"2016","unstructured":"Iwagami Y, Huang CK, Olsen MJ, et al. Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase 3beta in hepatocellular carcinoma. Hepatology. 2016;63:1213\u20131226.","journal-title":"Hepatology"},{"key":"6330_CR20","doi-asserted-by":"crossref","first-page":"e39981","DOI":"10.1371\/journal.pone.0039981","volume":"7","author":"H Koga","year":"2012","unstructured":"Koga H, Tsedensodnom O, Tomimaru Y, et al. Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS ONE. 2012;7:e39981.","journal-title":"PLoS ONE"},{"key":"6330_CR21","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/hep.26135","volume":"57","author":"CK Huang","year":"2013","unstructured":"Huang CK, Lee SO, Lai KP, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology. 2013;57:1550\u20131563.","journal-title":"Hepatology"},{"key":"6330_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60034-2","volume":"46","author":"LA Liotta","year":"1986","unstructured":"Liotta LA. Tumor invasion and metastases\u2013role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986;46:1\u20137.","journal-title":"Cancer Res"},{"key":"6330_CR23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/art.24250","volume":"60","author":"R Blaise","year":"2009","unstructured":"Blaise R, Mahjoub M, Salvat C, et al. Involvement of the Notch pathway in the regulation of matrix metalloproteinase 13 and the dedifferentiation of articular chondrocytes in murine cartilage. Arthritis Rheum. 2009;60:428\u2013439.","journal-title":"Arthritis Rheum"},{"key":"6330_CR24","doi-asserted-by":"crossref","first-page":"e95912","DOI":"10.1371\/journal.pone.0095912","volume":"9","author":"L Li","year":"2014","unstructured":"Li L, Zhao F, Lu J, et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappaB activation. PLoS ONE. 2014;9:e95912.","journal-title":"PLoS ONE"},{"key":"6330_CR25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2045-824X-3-2","volume":"3","author":"Y Funahashi","year":"2011","unstructured":"Funahashi Y, Shawber CJ, Sharma A, Kanamaru E, Choi YK, Kitajewski J. Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc Cell. 2011;3:2.","journal-title":"Vasc Cell"},{"key":"6330_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/jhep.2003.50296","volume":"38","author":"C Han","year":"2003","unstructured":"Han C, Demetris AJ, Michalopoulos GK, Zhan Q, Shelhamer JH, Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology. 2003;38:167\u2013177.","journal-title":"Hepatology"},{"key":"6330_CR27","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.18632\/oncotarget.3465","volume":"6","author":"LJ Wang","year":"2015","unstructured":"Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932\u20135946.","journal-title":"Oncotarget"},{"key":"6330_CR28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","volume":"44","author":"CK Ong","year":"2012","unstructured":"Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690\u2013693.","journal-title":"Nat Genet"},{"key":"6330_CR29","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","volume":"45","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470\u20131473.","journal-title":"Nat Genet"},{"key":"6330_CR30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:276\u2013282.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6330_CR31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252\u2013263.","journal-title":"Cancer Discov"},{"key":"6330_CR32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","volume":"6","author":"SK Saha","year":"2016","unstructured":"Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6:727\u2013739.","journal-title":"Cancer Discov"},{"key":"6330_CR33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","volume":"25","author":"EI Deryugina","year":"2006","unstructured":"Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9\u201334.","journal-title":"Cancer Metastasis Rev"},{"key":"6330_CR34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF02896015","volume":"25","author":"Y Li","year":"2005","unstructured":"Li Y, Zhang Y, Zheng Q. Expression of RECK gene and MMP-9 in hilar cholangiocarcinoma and its clinical significance. J Huazhong Univ Sci Technol Med Sci. 2005;25:552\u2013554.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"6330_CR35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-230X-9-30","volume":"9","author":"K Leelawat","year":"2009","unstructured":"Leelawat K, Sakchinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 2009;9:30.","journal-title":"BMC Gastroenterol"},{"key":"6330_CR36","first-page":"6157","volume":"7","author":"Q Sun","year":"2014","unstructured":"Sun Q, Zhao C, Xia L, et al. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma. Int J Clin Exp Pathol. 2014;7:6157\u20136164.","journal-title":"Int J Clin Exp Pathol"},{"key":"6330_CR37","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.91.15.7227","volume":"91","author":"S Jia","year":"1994","unstructured":"Jia S, McGinnis K, VanDusen WJ, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci U S A. 1994;91:7227\u20137231.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6330_CR38","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1073\/pnas.86.10.3609","volume":"86","author":"RS Gronke","year":"1989","unstructured":"Gronke RS, VanDusen WJ, Garsky VM, et al. Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc Natl Acad Sci U S A. 1989;86:3609\u20133613.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6330_CR39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156\u2013172.","journal-title":"Cell Res"},{"key":"6330_CR40","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1101\/gad.225334.113","volume":"27","author":"JH Tsai","year":"2013","unstructured":"Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27:2192\u20132206.","journal-title":"Genes Dev"},{"key":"6330_CR41","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.","journal-title":"Nat Commun"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06330-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06330-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06330-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T23:42:47Z","timestamp":1621640567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06330-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6330"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06330-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Animal studies in this manuscript have been approved by the Institutional Animal Care and Use Committee of Rhode Island Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animals rights"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}